SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SULLIVAN LOUIS W
(Last) (First) (Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET
(Street)
SILVER SPRING MD 20910
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/18/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/18/2024 M 15,000 A $175.43 31,260 D
Common Stock 12/18/2024 S 1,121 D $366.1077(1) 30,139 D
Common Stock 12/18/2024 S 600 D $366.9725(2) 29,539 D
Common Stock 12/18/2024 S 1,307 D $368.502(3) 28,232 D
Common Stock 12/18/2024 S 2,100 D $369.3155(4) 26,132 D
Common Stock 12/18/2024 S 1,400 D $370.295(5) 24,732 D
Common Stock 12/18/2024 S 1,501 D $373.1167(6) 23,231 D
Common Stock 12/18/2024 S 200 D $371.245 23,031 D
Common Stock 12/18/2024 S 2,451 D $374.1363(7) 20,580 D
Common Stock 12/18/2024 S 2,200 D $375.003(8) 18,380 D
Common Stock 12/18/2024 S 500 D $374.4554(9) 17,880 D
Common Stock 12/18/2024 S 200 D $379.3(10) 17,680 D
Common Stock 12/18/2024 S 700 D $380.12(11) 16,980 D
Common Stock 12/18/2024 S 620 D $381.4105(12) 16,360 D
Common Stock 12/18/2024 S 100 D $382.63 16,260 D
Common Stock 12/18/2024 S 752 D $368.6682(13) 15,508 D
Common Stock 12/18/2024 S 1,926 D $370.0152(14) 13,582 D
Common Stock 12/18/2024 S 100 D $370.78 13,482 D
Common Stock 12/18/2024 S 1,525 D $373.0584(15) 11,957 D
Common Stock 12/18/2024 S 1,962 D $374.1667(16) 9,995 D
Common Stock 12/18/2024 S 2,700 D $375.03(17) 7,295 D
Common Stock 12/18/2024 S 400 D $377.46 6,895 D
Common Stock 12/18/2024 S 944 D $379.6741(18) 5,951 D
Common Stock 12/18/2024 S 800 D $381.3738(19) 5,151 D
Common Stock 12/18/2024 S 100 D $382.245 5,051 D
Common Stock 12/19/2024 G 1,851 D $0.00 3,200 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options $175.43 12/18/2024 M 15,000 06/26/2016 06/26/2025 Common Stock 15,000 $0.00 0.00 D
Stock Options $183.98 07/08/2022 07/08/2031 Common Stock 3,230 3,230 I By Trust
Stock Options $240.2 07/07/2023 07/07/2032 Common Stock 2,490 2,490 I By Trust
Stock Options $229.81 07/13/2024 07/13/2033 Common Stock 4,560 4,560 I By Trust
Stock Options $336.37 07/25/2025 07/25/2034 Common Stock 1,440 1,440 I By Trust
Restricted Stock Unit $0.00(20) 07/25/2025 (21) Common Stock 590 590 I By Trust
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $365.475 to $366.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
2. This transaction was executed in multiple trades at prices ranging from $366.545 to $367.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $367.87 to $368.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $368.90 to $369.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $369.95 to $370.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $372.52 to $373.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $373.70 to $374.585. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $374.82 to $375.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
9. This transaction was executed in multiple trades at prices ranging from $377.16 to $378.065. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
10. This transaction was executed in multiple trades at prices ranging from $378.91 to $379.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
11. This transaction was executed in multiple trades at prices ranging from $380.10 to $380.135. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
12. This transaction was executed in multiple trades at prices ranging from $381.205 to $381.645. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
13. This transaction was executed in multiple trades at prices ranging from $368.49 to $369.355. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
14. This transaction was executed in multiple trades at prices ranging from $369.49 to $370.475. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
15. This transaction was executed in multiple trades at prices ranging from $372.55 to $373.395. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
16. This transaction was executed in multiple trades at prices ranging from $373.70 to $374.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
17. This transaction was executed in multiple trades at prices ranging from $374.83 to $375.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
18. This transaction was executed in multiple trades at prices ranging from $379.36 to $380.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
19. This transaction was executed in multiple trades at prices ranging from $380.88 to $381.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
20. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
21. Not applicable as restricted stock units do not have an expiration date.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney 12/19/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Grafico Azioni United Therapeutics (NASDAQ:UTHR)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di United Therapeutics
Grafico Azioni United Therapeutics (NASDAQ:UTHR)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di United Therapeutics